Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized dose-ranging ponatinib trial in resistant chronic phase CML
jRCT2080223237Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ponatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Takeda. Started Jun 2016; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2080223237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223237.